Clinical Trial: Belumosudil versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD (China)

China, Sept. 23 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Belumosudil versus Ruxolitinib for Steroid-Refractory or Breakthrough Hepatic cGVHD'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133154

Registration Time: 2026/09/22

Type: Interventional study

Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337597

Published by HT Digital Content Services with permission from Health Daily Digest....